President Trump will end federal subsidies that have helped millions of older Americans afford their Medicare prescription drug premiums, a policy shift that could raise out-of-pocket costs for seniors and inject a volatile new issue into the 2026 midterm election campaign.
The administration confirmed Tuesday that it will terminate the premium stabilization subsidies that were established under the Inflation Reduction Act passed during the Biden administration. The subsidies, which flow directly to Medicare Part D plans, have kept premium increases modest for the roughly 50 million Americans enrolled in the program.
Without the federal payments, insurance companies are expected to raise premiums significantly for the 2027 plan year. Policy analysts estimate that some beneficiaries could see their monthly premiums increase by 20 to 30 percent, though the exact impact will vary by plan and region.
The decision represents a major reversal of the Biden-era health care policy and delivers on a longstanding conservative goal of reducing federal involvement in drug pricing. Administration officials argued that the subsidies represented an improper government intervention in the insurance market and artificially distorted pricing signals.
Health and Human Services Secretary Xavier Becerra defended the move in a statement, saying it would restore market discipline to the Medicare prescription drug program. He argued that insurers would compete more aggressively on price and benefits without the federal backstop, potentially offsetting some of the premium increases.
Critics said the decision would fall hardest on low-income seniors and those with chronic health conditions who rely on expensive medications. Democratic lawmakers immediately seized on the issue, accusing the Trump administration of breaking a promise to protect Medicare beneficiaries.
Senator Bernie Sanders of Vermont called the move an attack on older Americans, noting that many seniors already struggle to afford their medications. House Minority Leader Hakeem Jeffries said Democrats would make the premium increases a central issue in the upcoming midterm campaigns.
The timing of the announcement, less than four months before the November midterm elections, has heightened the political stakes. Republicans have warned that raising the issue of Medicare costs could backfire, given the program’s popularity among older voters who turn out reliably at the polls.
But conservative policy groups applauded the decision. The Heritage Foundation and Americans for Prosperity issued statements praising the administration for rolling back what they described as an overreach of federal power into the health care market.
The end of the subsidies is just one of several health care policy changes the administration has pursued. Trump has also backed proposals to expand health savings accounts and to allow the importation of prescription drugs from Canada, though that initiative has faced regulatory and legal hurdles.
Medicare Part D, the prescription drug benefit created under President George W. Bush in 2003, is delivered through private insurance plans that receive federal subsidies. Premiums have fluctuated over the years, with the recent stabilization subsidies keeping increases well below historical averages.
Insurance industry executives have warned that the sudden removal of the subsidies could create market disruptions during the next open enrollment period. Some plans may exit certain markets or reduce the scope of their drug formularies to control costs.
Patient advocacy groups have begun preparing educational campaigns to help beneficiaries understand their options during the upcoming enrollment period. The Medicare open enrollment window runs from October 15 to December 7 each year.
The Centers for Medicare and Medicaid Services is expected to release detailed guidance on how the subsidy termination will be implemented in the coming weeks.
